Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch

Citius Pharmaceuticals, Inc.

LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.
Secured commercial supply agreements with CMOs; first-year launch supply already produced.
Submitted J-code application under HCPCS; secured inclusion in NCCN guidelines.
Designing patient assistance program and building specialized sales team for CTCL providers.
Exploring international licensing partnerships and expanded indications, including combination immunotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.